Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $15.96 down -5.39% from its previous closing price of $16.87. In other words, the price has decreased by -$5.39 from its previous closing price. On the day, 0.63 million shares were traded. SYRE stock price reached its highest trading level at $16.88 during the session, while it also had its lowest trading level at $15.66.
Ratios:
For a deeper understanding of Spyre Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.49 and its Current Ratio is at 6.49. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 08, 2025, initiated with a Outperform rating and assigned the stock a target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.
On September 04, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $45.Wedbush initiated its Outperform rating on September 04, 2024, with a $45 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’24 when Albers Jeffrey W. sold 6,700 shares for $36.76 per share. The transaction valued at 246,313 led to the insider holds 27,360 shares of the business.
Albers Jeffrey W. sold 300 shares of SYRE for $10,929 on Oct 25 ’24. The Director now owns 34,060 shares after completing the transaction at $36.43 per share. On Oct 25 ’24, another insider, SESSIONS, LLC, who serves as the Director of the company, bought 7,000 shares for $33.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 963999936 and an Enterprise Value of 609164544.
Stock Price History:
The Beta on a monthly basis for SYRE is 2.88, which has changed by -0.36792082 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.26, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is -1.78%, while the 200-Day Moving Average is calculated to be -22.58%.
Shares Statistics:
For the past three months, SYRE has traded an average of 569.47K shares per day and 626040 over the past ten days. A total of 60.74M shares are outstanding, with a floating share count of 51.32M. Insiders hold about 14.97% of the company’s shares, while institutions hold 99.81% stake in the company. Shares short for SYRE as of 1752537600 were 13602876 with a Short Ratio of 23.89, compared to 1749772800 on 12592074. Therefore, it implies a Short% of Shares Outstanding of 13602876 and a Short% of Float of 28.939999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Spyre Therapeutics Inc (SYRE) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.65 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.5 and -$3.0 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$3.26, with 8.0 analysts recommending between -$2.46 and -$4.15.
